Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the st…
$208.99-3.53%
报价 2026-11-06
市值
$10.91B
EV
$10.38B
PE (TTM)
–
预期 PE (FY2026)
39.7x
52 周区间距高点 -14.0%
$122.65$242.88
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07仅 EPS 线✗ 收入线✓ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 2.00 → 9.69（4.8x） | 21.6 |
| FY+32028-12 | 1.2x | 2.00 → 13.78（6.9x） | 15.2 |
毛利率 8% · TTM 收入 $43627M · 基数 EPS 2.00（调整后）
低毛利利润率驱动
研究结论
L2 2026-06-30全文 ↓尚未生成 L3 估值，没有三情景目标价。去生成估值 →
L2 报告格式无法提取要点，请看全文。
历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MOHMolina Healthcare, Inc. | $10.91B | -3.5% | -0.6% | 8.2% | – | 31.2x | 45.8x | |
| DVADaVita Inc. | $12.04B | -1.8% | +4.8% | 30.9% | 17.5x | 9.3x | 11.8x | |
| HALOHalozyme Therapeutics, Inc. | $11.76B | -15.7% | +27.0% | 78.2% | 29.3x | 20.9x | 15.2x | |
| AVTRAvantor, Inc. | $10.48B | +2.2% | +2.2% | 31.5% | 30.9x | 15.1x | 23.9x | |
| BIOBio-Rad Laboratories, Inc. | $10.25B | +3.4% | +0.1% | 51.9% | 9.4x | 9.6x | 27.2x | |
| HSICHenry Schein, Inc. | $9.59B | +0.9% | +5.8% | 31.8% | 24.9x | 12.7x | 17.8x | |
| GMEDGlobus Medical, Inc. | $9.54B | -12.8% | +9.9% | 67.4% | 21.9x | 13.9x | 16.5x | |
| ATRAptarGroup, Inc. | $9.03B | -1.1% | +8.7% | 27.8% | 22.0x | 11.1x | 25.3x | |
| HQYHealthEquity, Inc. | $8.57B | +0.2% | +7.6% | 69.5% | 32.7x | 23.7x | 19.7x | |
| 同行中位数 | – | – | +6.7% | 41.9% | 23.4x | 13.3x | 18.7x |
研究全文
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.58B | $10.87B | $10.8B | $11.38B | $11.48B | $11.43B | $11.15B | $10.5B |
| Gross Margin | 8.2% | 8.5% | 9.5% | 6.2% | 8.1% | 10.2% | 11.5% | 10.6% |
| Operating Margin | 1% | 1.3% | 0.8% | -1.4% | 1.2% | 3.3% | 3.9% | 3.6% |
| Net Income | $38M | $60M | $14M | $-160M | $79M | $255M | $298M | $251M |
| Diluted EPS | 0.74 | 1.19 | 0.27 | -2.77 | 1.5 | 4.74 | 5.45 | 4.35 |
| Operating Cash Flow | $-159M | $-294M | $1.08B | $-298M | $-125M | $-302M | $190M | $-224M |
研究材料
Filing 摘要